What Actually Reduces Cardiovascular Risk in Men Over 40: An Evidence-Ranked Guide

The interventions with the strongest evidence for reducing heart attacks, strokes, and cardiovascular death in men over 40 are, in order: sustained lifestyle change, blood pressure control, statin therapy, and — for men with diabetes or obesity — GLP-1 receptor agonists. Everything else is either adjunctive or still accumulating evidence.

Lifestyle First: The Evidence Is Unambiguous

Diet and exercise consistently outperform single-drug interventions in absolute risk reduction when maintained over years. The PREDIMED trial — a randomized study in high-risk adults — found that a Mediterranean diet supplemented with extra-virgin olive oil or nuts reduced the composite of heart attack, stroke, and cardiovascular death by roughly 28–30% compared to a low-fat control diet [8]. That number rivals or exceeds the benefit of moderate-intensity statin therapy in primary prevention populations.

Physical activity compounds the effect. ACC/AHA guidelines recommend 150 minutes per week of moderate-intensity aerobic activity, noting that structured exercise reduces systolic blood pressure by 5–8 mm Hg and improves insulin sensitivity within days of starting [1][2]. Smoking cessation sits at the top of the modifiable-risk hierarchy: risk of myocardial infarction drops substantially within two to five years of quitting and approaches never-smoker levels after roughly a decade [6].

If you want a structured read on which annual labs actually capture these risk factors early, see which health tests are actually worth running every year for men over 35.

Pharmacology: What the Trials Actually Show

Blood pressure control is the highest-yield pharmacologic intervention. ACC/AHA guidelines target <130/80 mm Hg for men with stage 1 hypertension (130–139/80–89 mm Hg) and 10-year ASCVD risk ≥10% [2][6]. Reducing systolic pressure by 10–12 mm Hg significantly cuts stroke and MI incidence. First-line generics — thiazide diuretics, ACE inhibitors, ARBs, calcium channel blockers — cost $4–$20/month, making this one of the best value interventions in preventive medicine.

Statins are next. Moderate-intensity statins deliver meaningful LDL reduction with a side-effect profile that high-intensity regimens worsen without proportionate benefit in most primary-prevention men [2]. For men with diabetes, GLP-1 receptor agonists add a layer of direct cardiovascular protection: the LEADER trial showed liraglutide reduced MACE by 13% (HR 0.87), and SUSTAIN-6 showed semaglutide cut the primary cardiovascular endpoint by 26% (HR 0.74) [2]. These aren't just weight-loss drugs for diabetic men — they're cardiovascular drugs that cause weight loss.

One finding that reshapes older clinical assumptions: the TRAVERSE trial (5,246 hypogonadal men aged 45–80) showed testosterone replacement therapy titrated to physiological levels was noninferior to placebo on MACE — no increase in cardiovascular death, MI, or stroke [2]. Men with documented hypogonadism don't need to avoid TRT on cardiac grounds; the evidence no longer supports that concern. If you're evaluating hormone optimization as part of a broader cardiovascular risk strategy, explore treatment options at our hormone optimization hub or compare vetted telehealth providers at DudeMeds.

On aspirin: primary prevention use is no longer well-supported. Bleeding risk offsets the modest event reduction in men without established ASCVD [2]. Don't take it prophylactically without a clear clinical indication.

For a broader look at how low testosterone intersects with energy, motivation, and cardiovascular markers, the research breakdown at low libido in men over 40 is worth reading alongside this guide.

Also worth noting: coronary artery calcium (CAC) scoring — typically $100–$400 out-of-pocket — is the most useful tool for resolving uncertainty in borderline-risk men (10-year ASCVD 7.5–20%). A CAC of zero permits reasonable deferral of statins in most cases; a score ≥100 strongly supports starting them [6]. It doesn't reduce risk itself, but it reliably tells you how aggressively to intervene. If you want a second clinical opinion on your risk picture, PeterMD's preventive cardiology consultations offer structured baseline assessments. You can also compare cardiovascular-focused providers across telehealth platforms to find one aligned with a prevention-first approach.

---

Related reading

• Which Supplements Actually Improve REM, Deep Sleep, and Sleep Latency in 2026
• Why Men on Anabolics Should Prioritize Cancer Screenings in 2026

Frequently asked questions

What is the single most effective thing a man over 40 can do to reduce cardiovascular risk?

Sustained lifestyle change — specifically adopting a Mediterranean-style diet and exercising 150+ minutes per week — produces the largest absolute cardiovascular risk reduction of any single intervention in primary prevention, supported by randomized trial data showing 28–30% relative risk reductions in major events [8]. Blood pressure control with medication is the highest-yield pharmacologic add-on when lifestyle alone is insufficient.

Does testosterone replacement therapy increase heart attack risk in men?

Testosterone replacement therapy titrated to normal physiological levels does not increase cardiovascular risk in hypogonadal men, based on the TRAVERSE trial, which enrolled over 5,000 men aged 45–80 and found no difference in cardiovascular death, MI, or stroke versus placebo [2]. The older concern about TRT and cardiac harm is not supported by current trial evidence when therapy is properly monit